Friday, September 11, 2020 9:01:30 PM
Randy ...so he was referring to the first interim in the video ...correct ?
In response to some of your earlier posts ...re not developing the drug earlier ......The earlier variations of Covid ...MERS etc burnt them selves out fairly fast so less incentive for anyone to put $50m plus putting the drug thru the clinical trials ...also difficulty of enrolling a placebo controlled trial if the available pool of infected people is shrinking .
Covid 19 is different ...VERY infectious and still very widespread .
I know this board is speculating on partners etc BUT IMHO the most important PR we should concern ourselves with is a PR stating the IV trial is fully enrolled . That gives us a count down to results.
If the results are excellent ...limited partnering on drug production and distribution will happen very fast .
Kiwi
In response to some of your earlier posts ...re not developing the drug earlier ......The earlier variations of Covid ...MERS etc burnt them selves out fairly fast so less incentive for anyone to put $50m plus putting the drug thru the clinical trials ...also difficulty of enrolling a placebo controlled trial if the available pool of infected people is shrinking .
Covid 19 is different ...VERY infectious and still very widespread .
I know this board is speculating on partners etc BUT IMHO the most important PR we should concern ourselves with is a PR stating the IV trial is fully enrolled . That gives us a count down to results.
If the results are excellent ...limited partnering on drug production and distribution will happen very fast .
Kiwi
Recent RLFTF News
- MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank • ACCESS Newswire • 03/19/2026 06:35:00 AM
- MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics • ACCESS Newswire • 12/23/2025 06:20:00 AM
- Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics • ACCESS Newswire • 12/15/2025 06:20:00 AM
- Relief Therapeutics Shareholders Approve Business Combination with NeuroX • ACCESS Newswire • 11/14/2025 05:40:00 PM
- Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 • ACCESS Newswire • 10/29/2025 06:20:00 AM
- Micro-Cap Biotech Skyrockets on FDA Pediatric Disease Nod • AllPennyStocks.com • 05/22/2025 04:49:00 PM
